Communiqués CVRx, Inc.

Actions

CVRX

US1266381052

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX 16:39:31 06/10/2026			Varia. 5j.	Varia. 1 janv.
1,565 ^USD	+0,32%		-40,33%	-77,90%

29/09	CVRx, Inc. annonce des données de dernière minute et de nouvelles données cliniques sur Barostim lors du congrès scientifique annuel 2026 de la Société américaine de l’insuffisance cardiaque	CI
21/09	Nyxoah nomme Loic Moreau au poste de directeur financier par intérim suite au départ de John Landry	MT

Communiqués

29/09	CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026	AQ
21/09	CVRx Appoints John Landry as Chief Financial Officer	AQ
25/08	CVRx Responds to Letter from Pointillist Family Office	AQ
24/08	CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy	AQ
11/08	CVRx Announces Sales Leadership Transition	AQ
07/08	CVRx : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
07/08	CVRx: Q2 Earnings Snapshot	AQ
06/08	CVRx Reports Second Quarter 2026 Financial and Operating Results	AQ
28/07	CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference	AQ
23/07	CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026	AQ
09/06	CVRx Announces Chief Financial Officer Transition	AQ
27/05	CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	AQ
20/05	CVRx to Present at the William Blair 46th Annual Growth Stock Conference	AQ
14/05	CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy	AQ
11/05	CVRx: Q1 Earnings Snapshot	AQ
11/05	CVRx Reports First Quarter 2026 Financial and Operating Results	AQ
04/05	CVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population	AQ
27/04	CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026	AQ
20/04	CVRx Announces Nomination of Michael Dale for Election to the Board of Directors	AQ
13/04	CVRx Reports Preliminary First Quarter 2026 Financial Results	AQ
02/03	CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting	AQ
12/02	CVRx: Q4 Earnings Snapshot	AQ
12/02	CVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating Results	AQ
29/01	CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026	AQ
22/01	CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population	AQ